foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Building a thriving life sciences hub in the Nordi...

On Thursday 30 August, an expert panel will take to the stage at the inaugu...

Read More

Unlocking Potential in the Nordic Life Sciences Se...

In 2017, life science companies in Scandinavia raised almost $2.2 billion t...

Read More

Investorview: Why people are key in life science i...

Since it was founded in 1996, European venture capital firm HealthCap has i...

Read More

Investorview: Plugging knowledge gaps to accelerat...

Venture capital firm Hadean Ventures closed its first fund at the end of 20...

Read More

Xplico: Supporting strategic decision-making throu...

Key learnings: Headquartered in Copenhagen, Xplico has been providing valua...

Read More

PhoreMost raises £11m Series A round to progress t...

Key learnings: PhoreMost completed its Series A round in May 2018, with a t...

Read More

What are the obstacles to securing investment in l...

More than one third (35%) of investor respondents feel that under a quarter...

Read More

Have your say in the LSX C-Suite Challenges in Lif...

What are the biggest obstacles to securing financing? What challenges do yo...

Read More

Investorview: Driving early-stage investment in UK...

In March 2018, NCL Technology Ventures launched a £50 million fund to help ...

Read More

NMD Pharma to advance neuromuscular disorder thera...

Key learnings:

Read More

EQS Group: Leveraging technology for effective reg...

Key learnings: EQS Group’s range of digital services supports companies in ...

Read More

Investorview: Committing to social responsibility ...

Swiss venture capital firm MTIP launched its first fund in 2016, achieving ...

Read More

Add Your Response